Grade 4 neutropenia according to the Common Terminology Criteria for Adverse Events (CTCAE; version 5.0) [1] occurred during the first course, necessitating administration of granulocyte colony stimulating factor. This evidence concerns the gene CSF3 and Decreased total neutrophil count.